The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

The company's modest market multiple, combined with robust growth prospects and a fortress-like balance sheet, reflects management's disciplined approach to building long-term value. Few biotechs ...

making Vertex stock a worthwhile buy in 2025. Don’t miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks?

More than 60 WBUR listeners and readers shared their stories — and photos — with us to collectively commemorate, rage and ...

James also mentioned wanting to build himself these DIY viewfinders for his compact cameras without tilt screens, so he can shoot from the hip with them. As he also noted, it’s a great opportunity to ...

DeepSeek's DeepThink R1 built a playable Pac-Man game in minutes with minimal input. We tested its reasoning, coding, and ...

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock remains a compelling buy right now. Image source: Getty Images.